Ava has raised 30 million U.S. dollars in a Series B funding round, announced the company in a statement. The majority of the new financing came from existing investors including the venture capital firms btov and SVC. Credit Suisse’s investment arm was also involved.
To help women determine their fertile days, the medtech company developed a tracking bracelet that links to a smart phone and can measure physiological parameters such as resting heart rate, skin temperature, heart rate variability, breathing rate, circulation and heat loss. The wearer’s smart phone then evaluates the data to identify fertile days.
Ava, which was founded in Zurich in 2014 and launched the bracelet in July 2016, intends to use the new funds to research other areas of application for its bracelet, such as contraception. It ultimately aims to give women control of their reproductive health.
Coinciding with the successful funding round, Ava announced a milestone of 10,000 pregnancies achieved with the bracelet's help.
More News
Contact us
Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center?
info@greaterzuricharea.com